The level of hemophilia care has significantly improved over the last few decades. Despite all improvements, the development and management of neutralizing antibodies i.e. inhibitors remains a major complication to treatment with factor concentrates.

The aim of this course is to summarize and highlight the current pre-clinical and clinical knowledge in the inhibitor area in an interactive way based on lectures and case discussions.

Target group: Physicians treating hemophilia from all over the world. Participants should be affiliated to a hemophilia centre, have been working in the area for at least one year and have a proven future commitment to this field. Good English-speaking skills are required.

The course is a collaboration between Lund University and Skåne University Hospital (Malmö Centre for Thrombosis and Haemostasis).

LIPUS (Institute for the Professional Development of Physicians in Sweden) will review the course (www.lipus.se).
CME (Continuing Medical Education) application pending.

Closing date for applications: 27 August 2018.

The course is sponsored by Shire, excluding the costs of travel and accommodation.